AI Engines For more Details: Perplexity Kagi Labs You
Antibacterial Action: Sulfaguanidine works by inhibiting the growth and reproduction of bacteria. It achieves this by interfering with the synthesis of folic acid, which is essential for the bacteria's survival. By blocking the production of folic acid, sulfaguanidine prevents bacteria from multiplying and eventually leads to their death.
Gastrointestinal Infections: Sulfaguanidine is commonly used to treat gastrointestinal infections, including bacterial gastroenteritis and enteric infections caused by susceptible organisms such as Escherichia coli, Salmonella, Shigella, and Campylobacter species. These infections often present with symptoms like diarrhea, abdominal pain, nausea, and vomiting.
Traveler's Diarrhea: Sulfaguanidine may be prescribed to travelers as a prophylactic treatment for diarrhea caused by bacterial pathogens commonly encountered in certain regions. It can help reduce the risk of developing traveler's diarrhea and alleviate symptoms if an infection occurs.
Inflammatory Bowel Disease (IBD): In some cases, sulfaguanidine may be used as an adjunctive treatment for inflammatory bowel diseases such as ulcerative colitis. It can help reduce inflammation in the intestinal lining and control symptoms such as diarrhea and rectal bleeding.
Dosage and Administration: Sulfaguanidine is typically administered orally in the form of tablets or suspension. The dosage and duration of treatment depend on the severity of the infection, the patient's age and weight, and other factors. It is essential to follow the prescribed dosage and complete the full course of treatment to ensure effective eradication of the infection.
Adverse Effects: Common side effects of sulfaguanidine may include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal discomfort. Allergic reactions such as rash, itching, and swelling may also occur in some individuals. In rare cases, sulfaguanidine may cause more severe adverse effects such as blood disorders or liver toxicity.
Precautions and Contraindications: Sulfaguanidine should be used with caution in patients with a history of sulfa allergy or hypersensitivity reactions to sulfonamide antibiotics. It is contraindicated in individuals with severe liver or kidney dysfunction, blood disorders, or porphyria. Pregnant women, breastfeeding mothers, and pediatric patients should also use sulfaguanidine cautiously under medical supervision.
Drug Interactions: Sulfaguanidine may interact with other medications, including oral anticoagulants, oral hypoglycemic agents, diuretics, and certain anticonvulsants. It is essential to inform the healthcare provider about all medications, supplements, and herbal products being taken to avoid potential drug interactions.
Resistance: Like other antibiotics, the overuse or misuse of sulfaguanidine can contribute to the development of bacterial resistance. Therefore, it is crucial to use sulfaguanidine judiciously and only when indicated to preserve its effectiveness for future use.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 0.6 | 0.6 | |
| Allergic Rhinitis (Hay Fever) | 1.2 | 0.9 | 0.33 |
| Allergies | 1.8 | 0.6 | 2 |
| Allergy to milk products | 1.2 | 0.9 | 0.33 |
| Alzheimer's disease | 1.5 | 1.8 | -0.2 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.9 | 0.9 | 0 |
| Ankylosing spondylitis | 1.8 | 0.6 | 2 |
| Anorexia Nervosa | 0.6 | 1.2 | -1 |
| Antiphospholipid syndrome (APS) | 0.9 | 0.9 | |
| Asthma | 1.7 | 0.6 | 1.83 |
| Atherosclerosis | 1.5 | 1.5 | |
| Atrial fibrillation | 1.2 | 0.9 | 0.33 |
| Autism | 1.8 | 2.4 | -0.33 |
| Autoimmune Disease | 0.9 | 0.9 | |
| Barrett esophagus cancer | 0.3 | -0.3 | |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 0.9 | 0.9 | |
| Bipolar Disorder | 1.2 | 0.3 | 3 |
| Brain Trauma | 0.3 | 0.6 | -1 |
| Breast Cancer | 0.6 | 0.6 | |
| Cancer (General) | 0.5 | -0.5 | |
| Carcinoma | 1.5 | 0.6 | 1.5 |
| Celiac Disease | 1.5 | 0.6 | 1.5 |
| Cerebral Palsy | 0.6 | 0.6 | 0 |
| Chronic Fatigue Syndrome | 1.6 | 0.9 | 0.78 |
| Chronic Kidney Disease | 0.9 | 0 | 0 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.2 | 0.3 | 3 |
| Chronic Urticaria (Hives) | 1.5 | 0.3 | 4 |
| Coagulation / Micro clot triggering bacteria | 1.5 | 0.6 | 1.5 |
| Cognitive Function | 0.9 | 0.3 | 2 |
| Colorectal Cancer | 2.9 | 0.9 | 2.22 |
| Constipation | 1.2 | 1.2 | |
| Coronary artery disease | 1.8 | 0.6 | 2 |
| COVID-19 | 2.1 | 1.2 | 0.75 |
| Crohn's Disease | 2.4 | 0.9 | 1.67 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 1.2 | 0.3 | 3 |
| d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
| deep vein thrombosis | 1.5 | 0.9 | 0.67 |
| Denture Wearers Oral Shifts | 0.6 | 0.6 | |
| Depression | 2.8 | 2 | 0.4 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 0.9 | 0.9 | 0 |
| Endometriosis | 1.8 | 0.9 | 1 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 2.1 | 0.3 | 6 |
| erectile dysfunction | 0.9 | 0.9 | |
| Fibromyalgia | 0.3 | -0.3 | |
| Functional constipation / chronic idiopathic constipation | 2.4 | 0.9 | 1.67 |
| gallstone disease (gsd) | 1.8 | 1.8 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 0.3 | 0 |
| Generalized anxiety disorder | 1.8 | 0.6 | 2 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.9 | 0.9 | |
| Graves' disease | 0.6 | 0.9 | -0.5 |
| Gulf War Syndrome | 0.3 | 0.3 | 0 |
| Halitosis | 0.6 | 0.3 | 1 |
| Hashimoto's thyroiditis | 0.9 | 0.3 | 2 |
| Heart Failure | 2.1 | 0.3 | 6 |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| High Histamine/low DAO | 0.6 | 0.3 | 1 |
| hypercholesterolemia (High Cholesterol) | 0.6 | 0.6 | |
| hyperglycemia | 1.5 | 0.3 | 4 |
| hypertension (High Blood Pressure | 1.5 | 1.2 | 0.25 |
| Hypoxia | 1.5 | 1.5 | |
| IgA nephropathy (IgAN) | 0.9 | 0.9 | |
| Inflammatory Bowel Disease | 2.3 | 1.8 | 0.28 |
| Insomnia | 0.9 | 0.9 | 0 |
| Intelligence | 0.9 | 0.9 | |
| Intracranial aneurysms | 0.6 | 0.6 | |
| Irritable Bowel Syndrome | 2.4 | 0.9 | 1.67 |
| ischemic stroke | 1.5 | 0.9 | 0.67 |
| Liver Cirrhosis | 2.6 | 1.5 | 0.73 |
| Long COVID | 1.2 | 0.6 | 1 |
| Lung Cancer | 0.6 | 0.3 | 1 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.9 | 0.3 | 2 |
| ME/CFS with IBS | 0.3 | 0.3 | 0 |
| ME/CFS without IBS | 0.3 | 0.3 | 0 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.3 | |
| Metabolic Syndrome | 2.4 | 1.2 | 1 |
| Mood Disorders | 2.2 | 2 | 0.1 |
| multiple chemical sensitivity [MCS] | 0.6 | 0.6 | |
| Multiple Sclerosis | 1.5 | 1.2 | 0.25 |
| Multiple system atrophy (MSA) | 0.3 | -0.3 | |
| myasthenia gravis | 0.9 | 0.9 | |
| neuropathic pain | 0.3 | -0.3 | |
| Neuropathy (all types) | 0.3 | 0.6 | -1 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.9 | 0.9 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.1 | 0.6 | 2.5 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
| Obesity | 2.1 | 1.9 | 0.11 |
| obsessive-compulsive disorder | 2.1 | 0.6 | 2.5 |
| Osteoarthritis | 1.2 | 0.9 | 0.33 |
| Osteoporosis | 1.2 | 0.6 | 1 |
| pancreatic cancer | 0.3 | 0.3 | 0 |
| Parkinson's Disease | 2.4 | 1.8 | 0.33 |
| Polycystic ovary syndrome | 1.8 | 0.9 | 1 |
| primary biliary cholangitis | 0.3 | 0.3 | 0 |
| Primary sclerosing cholangitis | 0.6 | 0.3 | 1 |
| Psoriasis | 1.5 | 0.3 | 4 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.5 | 0.6 | 1.5 |
| Rosacea | 0.3 | 0.3 | |
| Schizophrenia | 0.9 | 0.6 | 0.5 |
| scoliosis | 0.6 | 0.3 | 1 |
| Sjögren syndrome | 0.9 | 0.3 | 2 |
| Sleep Apnea | 0.3 | 0.6 | -1 |
| Slow gastric motility / Gastroparesis | 1.2 | 1.2 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.2 | 1.2 | |
| Stress / posttraumatic stress disorder | 0.9 | 0.3 | 2 |
| Systemic Lupus Erythematosus | 1.5 | 0.3 | 4 |
| Tic Disorder | 0.6 | 0.6 | |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 1.8 | 0.9 | 1 |
| Type 2 Diabetes | 2.4 | 1.8 | 0.33 |
| Ulcerative colitis | 2.1 | 0.9 | 1.33 |
| Unhealthy Ageing | 0.9 | 0.9 | |
| Vitiligo | 1.2 | 1.2 |
